
|Articles|May 19, 2022
The Biosimilars That May Compete With Humira Starting Next Year
Author(s)MHE Staff
A list of biosimilar competitors to Humira that may come on the market next year.
Advertisement
Advertisement
Related Content
Advertisement





Switching to Eylea HD extends injection intervals in DME patients | ASRS 2026
Published: | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
TKI axitinib beats anti-VEGF therapy in wet AMD in phase 3 trial | ASRS 2026
2
Bevacizumab surpasses Eylea as the most common retinal disease injection | ASRS 2026
3
FDA approves Lipfendra, first oral PCSK9 inhibitor
4
Phase 3 trial confirms efficacy of tarcocimab in diabetic retinopathy | ASRS 2026
5






















